The article, published in the Journal of Clinical Research & Bioethics, analyzed 22 clinical studies of bupivacaine liposome injectable suspension, including phase III clinical trials and post-market studies and compared them with a medical review of the new drug application from the U.S. Food and Drug Administration.
Access the article here.
More articles on spine:
Can risk sharing work? The realities of reducing low-value spine care
Pedicle subtraction osteotomy revision — 5 things to know
D Magazine honors Spine Team Texas physicians
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
